EA201992299A1 - Соединения на основе ингибиторов ask1 и их применение - Google Patents

Соединения на основе ингибиторов ask1 и их применение

Info

Publication number
EA201992299A1
EA201992299A1 EA201992299A EA201992299A EA201992299A1 EA 201992299 A1 EA201992299 A1 EA 201992299A1 EA 201992299 A EA201992299 A EA 201992299A EA 201992299 A EA201992299 A EA 201992299A EA 201992299 A1 EA201992299 A1 EA 201992299A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
application
compounds based
ask1 inhibitors
methods
Prior art date
Application number
EA201992299A
Other languages
English (en)
Inventor
Сэмюэл Дэвид Браун
Original Assignee
Сил Рок Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сил Рок Терапьютикс, Инк. filed Critical Сил Рок Терапьютикс, Инк.
Publication of EA201992299A1 publication Critical patent/EA201992299A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Abstract

В настоящем изобретении описаны соединения, включая их фармацевтически приемлемые соли, сольваты, метаболиты, пролекарства, способы получения таких соединений, фармацевтические композиции, содержащие такие соединения, и способы применения таких соединений для лечения неалкогольного стеатогепатита и других заболеваний, характеризующихся дисфункциональным восстановлением ткани и фиброзом.
EA201992299A 2017-04-05 2018-04-04 Соединения на основе ингибиторов ask1 и их применение EA201992299A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762482085P 2017-04-05 2017-04-05
PCT/US2018/026134 WO2018187506A1 (en) 2017-04-05 2018-04-04 Ask1 inhibitor compounds and uses thereof

Publications (1)

Publication Number Publication Date
EA201992299A1 true EA201992299A1 (ru) 2020-03-26

Family

ID=63712299

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992299A EA201992299A1 (ru) 2017-04-05 2018-04-04 Соединения на основе ингибиторов ask1 и их применение

Country Status (27)

Country Link
US (2) US20210087167A1 (ru)
EP (1) EP3606519A4 (ru)
JP (1) JP7196093B2 (ru)
CN (1) CN110730661B (ru)
AR (1) AR111407A1 (ru)
AU (1) AU2018250217B2 (ru)
BR (1) BR112019021021A2 (ru)
CA (1) CA3059107A1 (ru)
CL (1) CL2019002810A1 (ru)
CO (1) CO2019011708A2 (ru)
CR (1) CR20190503A (ru)
CU (1) CU20190080A7 (ru)
DO (1) DOP2019000255A (ru)
EA (1) EA201992299A1 (ru)
EC (1) ECSP19078393A (ru)
IL (1) IL269711B (ru)
JO (1) JOP20190221A1 (ru)
MA (1) MA49047A (ru)
MX (1) MX2019012013A (ru)
NI (1) NI201900102A (ru)
NZ (1) NZ758345A (ru)
PE (1) PE20200009A1 (ru)
PH (1) PH12019502288A1 (ru)
RU (1) RU2019134679A (ru)
SG (1) SG11201909155VA (ru)
TW (1) TWI779022B (ru)
WO (1) WO2018187506A1 (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10787435B2 (en) * 2017-01-22 2020-09-29 Fuijan Cosunter Pharmaceutical Co. Ltd. ASK1 inhibitor and preparation method and use thereof
WO2018209354A1 (en) 2017-05-12 2018-11-15 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
CN111801314B (zh) 2018-01-02 2023-10-31 西尔洛克治疗公司 Ask1抑制剂化合物及其用途
CN110407806B (zh) * 2018-04-28 2021-08-17 深圳微芯生物科技股份有限公司 甲酰胺类化合物、其制备方法及其应用
AU2019262016A1 (en) 2018-05-02 2020-11-19 Enanta Pharmaceuticals, Inc. Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
US10654833B2 (en) 2018-06-28 2020-05-19 Hepatikos Therapeutics, Llc ASK1 isoindolin-1-one inhibitors and methods of use thereof
WO2020041417A1 (en) 2018-08-22 2020-02-27 Enanta Pharmaceuticals, Inc. Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
US11345699B2 (en) 2018-11-19 2022-05-31 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
US11466033B2 (en) 2019-03-25 2022-10-11 Enanta Pharmaceuticals, Inc. Substituted pyridines as apoptosis signal-regulating kinase 1 inhibitors
CN112409332B (zh) * 2019-08-23 2023-12-08 广东东阳光药业股份有限公司 三氮唑衍生物及其在药物中的应用
BR112022012641A2 (pt) 2019-12-27 2022-09-06 Lupin Ltd Compostos tricíclicos substituídos
MX2022013401A (es) 2020-05-01 2022-11-14 Pfizer Compuestos de azalactama como inhibidores de hpk1.
WO2021224818A1 (en) * 2020-05-08 2021-11-11 Pfizer Inc. Isoindolone compounds as hpk1 inhibitors
WO2024020458A1 (en) * 2022-07-20 2024-01-25 Seal Rock Therapeutics, Inc. Method of treating organ diseases or disorders with ask1 inhibitors

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4229447A (en) 1979-06-04 1980-10-21 American Home Products Corporation Intraoral methods of using benzodiazepines
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4755386A (en) 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
US5739136A (en) 1989-10-17 1998-04-14 Ellinwood, Jr.; Everett H. Intraoral dosing method of administering medicaments
TWI598347B (zh) 2009-07-13 2017-09-11 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
WO2011097079A1 (en) * 2010-02-03 2011-08-11 Takeda Pharmaceutical Company Limited Apoptosis signal-regulating kinase 1 inhibitors
WO2012079022A1 (en) * 2010-12-10 2012-06-14 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
EP2651417B1 (en) 2010-12-16 2016-11-30 Calchan Limited Ask1 inhibiting pyrrolopyrimidine derivatives
NZ729678A (en) * 2014-09-24 2018-07-27 Gilead Sciences Inc Methods of treating non-alcoholic steatohepatitis using ask1 inhibitor in combination with a fxr agonist
WO2017214359A1 (en) 2016-06-10 2017-12-14 Venenum Biodesign Llc Novel clostridium difficile toxin inhibitors
US10787435B2 (en) * 2017-01-22 2020-09-29 Fuijan Cosunter Pharmaceutical Co. Ltd. ASK1 inhibitor and preparation method and use thereof
KR102089234B1 (ko) 2017-01-22 2020-05-15 푸젠 코선터 파마슈티컬 컴퍼니 리미티드 Ask1 억제제로서의 피리딘 유도체 및 이의 제조방법과 용도
US11168095B2 (en) 2017-02-07 2021-11-09 Biogen Ma Inc. ASK1 inhibiting agents
WO2018149284A1 (zh) 2017-02-16 2018-08-23 四川科伦博泰生物医药股份有限公司 激酶抑制剂及其制备方法和用途
WO2018151830A1 (en) 2017-02-17 2018-08-23 Fronthera U.S. Pharmaceuticals Llc Pyridinyl based apoptosis signal-regulation kinase inhibitors
WO2018157277A1 (en) 2017-02-28 2018-09-07 Eli Lilly And Company Isoquinolin and naphthydrin compounds
CN111094250B (zh) 2017-03-03 2022-11-04 江苏豪森药业集团有限公司 凋亡信号调节激酶抑制剂及其制备方法和应用
EP3601250A4 (en) 2017-03-27 2020-11-25 Pharmakea, Inc. APOPTOSIS SIGNAL REGULATION KINASE 1 (ASK 1) INHIBITOR COMPOUNDS
WO2019055540A1 (en) 2017-09-13 2019-03-21 D.E. Shaw Research, Llc COMPOUNDS AS INHIBITORS OF RAS AND THEIR USE
US10654833B2 (en) * 2018-06-28 2020-05-19 Hepatikos Therapeutics, Llc ASK1 isoindolin-1-one inhibitors and methods of use thereof

Also Published As

Publication number Publication date
ECSP19078393A (es) 2019-12-27
CN110730661A (zh) 2020-01-24
JOP20190221A1 (ar) 2019-09-23
US10150755B2 (en) 2018-12-11
CO2019011708A2 (es) 2020-01-17
CL2019002810A1 (es) 2020-03-27
AU2018250217A1 (en) 2019-11-07
CU20190080A7 (es) 2020-10-20
CR20190503A (es) 2020-02-28
IL269711A (en) 2019-11-28
RU2019134679A (ru) 2021-05-05
IL269711B (en) 2021-12-01
TW201838983A (zh) 2018-11-01
EP3606519A4 (en) 2020-12-02
NI201900102A (es) 2020-05-15
PE20200009A1 (es) 2020-01-06
JP7196093B2 (ja) 2022-12-26
CA3059107A1 (en) 2018-10-11
US20180291002A1 (en) 2018-10-11
AR111407A1 (es) 2019-07-10
WO2018187506A1 (en) 2018-10-11
PH12019502288A1 (en) 2020-07-13
SG11201909155VA (en) 2019-10-30
NZ758345A (en) 2022-02-25
BR112019021021A2 (pt) 2020-05-05
JP2020515589A (ja) 2020-05-28
MX2019012013A (es) 2019-12-18
CN110730661B (zh) 2023-06-13
US20210087167A1 (en) 2021-03-25
AU2018250217B2 (en) 2022-05-19
MA49047A (fr) 2020-02-12
DOP2019000255A (es) 2019-12-15
TWI779022B (zh) 2022-10-01
EP3606519A1 (en) 2020-02-12
KR20190141166A (ko) 2019-12-23

Similar Documents

Publication Publication Date Title
EA201992299A1 (ru) Соединения на основе ингибиторов ask1 и их применение
PH12021500014A1 (en) Fused ring compounds
CY1124404T1 (el) Παραγωγα χολικου οξεος ως αγωνιστες fxr/tgr5 και μεθοδοι χρησης αυτων
EA201792214A1 (ru) Соединения замещенного хиназолина
EA201991403A1 (ru) Модулятор регулятора трансмембранной проводимости при муковисцидозе, фармацевтические композиции, способы лечения и способ получения указанного модулятора
EA201890307A1 (ru) Индазольные и азаиндазольные соединения как ингибиторы irak-4
EA201691302A1 (ru) Новые гетероциклические соединения
EA202092490A1 (ru) Модуляторы метилмодифицирующих ферментов, композиции и их применения
MX2022005232A (es) Degradadores de moleculas peque?as de helios y procedimientos de uso.
EA201692268A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
JOP20200059A1 (ar) مركبات تنشيط القسيم العضلي ثنائي الأميد واستخداماتها
PH12017500029A1 (en) 4,5-dihydroisoxazole derivatives as nampt inhibitors
EA202191519A1 (ru) Модуляторы trex1
EA201991700A1 (ru) Селективные ингибиторы jak1
CY1124251T1 (el) Παραγωγα καρβοξαμιδιου
MX2021007247A (es) Derivados de rapamicina.
UY36123A (es) Derivados de carboxamida
MX2020011756A (es) Compuesto farmaceutico, sales del mismo, formulaciones del mismo y metodos para hacer y usar el mismo.
NZ740587A (en) Fluoroindole derivatives as muscarinic m1 receptor positive allosteric modulators
EA202191192A1 (ru) Кристаллические соли ингибитора плазменного калликреина
EA201891319A1 (ru) Соединения алкилдигидрохинолинсульфонамида
EA201891680A1 (ru) Производные индана в качестве модуляторов mglur7
TW201713630A (en) Substituted quinazoline compounds and methods of use thereof
BR112018003335A2 (pt) composições farmacêuticas compreendendo 3-(5-amino-2-metil-4-oxo-4h-quinazolina-3-il)-piperidina-2,6-diona
MX2021011081A (es) Derivados de nicorandil.